Use of tiotropium Respimat versus HandiHaler and mortality in patients with COPD Source: Eur Respir J 2014; 43: 1818-1819 Year: 2014
Use of tiotropium Respimat versus HandiHaler and mortality in patients with COPD Source: Eur Respir J 2014; 43: 1816-1818 Year: 2014
Efficacy in COPD patients of tiotropium administered via the Respimat® Soft MistÔ Inhaler (SMI) compared to HandiHaler® (HH) Source: Eur Respir J 2006; 28: Suppl. 50, 431s Year: 2006
Dose-response to tiotropium administered via the Respimat® Soft MistÔ Inhaler (SMI) to patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 318s Year: 2006
COPD and asthma patients are satisfied with handling and inhalation characteristics of Soft Mist InhalerÔ (Berodual® Respimat®) Source: Eur Respir J 2006; 28: Suppl. 50, 739s Year: 2006
Lung function indices for predicting mortality in COPD Source: Eur Respir J 2013; 42: 616-625 Year: 2013
Preference for novel soft mist inhaler over pMDI in patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 88s Year: 2004
Formoterol Aerolizer inhaler technique in patients with Asthma and COPD Source: International Congress 2017 – Pulmonary drug and devices delivery Year: 2017
Comparison of the pharmacokinetics and pharmacodynamics of once daily tiotropium Respimat® and tiotropium HandiHaler® in COPD patients Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013
Mixed treatment analysis comparing tiotropium HandiHaler® and Respimat® Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014
Patient inhaler satisfaction with Spiromax Budesonide/Formoterol versus Diskus Fluticasone/Salmeterol in COPD Source: International Congress 2019 – Inhalers: adherence and preference Year: 2019
Increased risk of mortality in COPD patients using tiotropium respimat vs. tiotropium Handihaler Source: Annual Congress 2012 - Exacerbations of asthma and COPD: assessment, impact and novel treatments Year: 2012
Efficacy of once-daily tiotropium Respimat in adults with asthma based on GINA Steps 2–5 Source: International Congress 2017 – Bronchial asthma management Year: 2017
Switch to Budesonide/Formoterol Easyhaler Inhalation from other inhalers in asthma patients; A real-life study Source: International Congress 2018 – Pulmonary drug delivery: inhaler use, devices and technologies Year: 2018
Effect of switching from salmeterol/fluticasone dry powder inhaler to formoterol/fluticasone pressurized metered-dose inhaler in elderly asthma patients Source: International Congress 2016 – Asthma management Year: 2016
Assessment of a ventilator circuit adapter to be used in conjunction with the Respimat* Soft Mist Inhaler (SMI) Source: International Congress 2017 – COPD and weaning Year: 2017
Efficacy and safety of extrafine glycopyrronium bromide pMDI (CHF 5259) in COPD patients Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016
Lung deposition of formoterol in COPD patients: comparison of formoterol HFA pMDI, and formoterol dry powder inhaler Source: Eur Respir J 2007; 30: Suppl. 51, 100s Year: 2007
Plume temperature and force of fluticasone propionate/formoterol pMDI compared with fluticasone propionate/salmeterol pMDI Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014